DNA damage is able to induce senescence in tumor cells in vitro and in vivo

Cancer Research

Volumn 62, Issue 6, 2002, Pages 1876-1883

  te Poele, Robert H ^a   Okorokov, Andrei L ^b   Jardine, Lesley ^c   Cummings, Jeffrey ^c   Joel, Simon P ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; PROTEIN P53;

ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; COLON CARCINOMA; DNA DAMAGE; DRUG EFFECT; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; SENESCENCE; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BETA-GALACTOSIDASE; BREAST NEOPLASMS; CAMPTOTHECIN; CELL AGING; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA DAMAGE; ETOPOSIDE; HUMANS; NEOADJUVANT THERAPY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037086268     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. The limited in vitro lifetime of human diploid cell strains
2. A biomarker that identifies senescent human cells in culture and in aging skin in vivo
3. Cellular senescence revisited: A review
4. Role of the cyclin-dependent kinase inhibitors in the development of cancer
5. Somatic point mutations in the p53 gene of human tumors and cell lines: Updated compilation
6. p53 in growth control and neoplasia
7. p53: Puzzle and paradigm
8. p53, the cellular gatekeeper for growth and division
9. p53 and the Li-Fraumeni syndrome
10. Tumor spectrum analysis in p53-mutant mice
11. WAF1, a potential mediator of p53 tumor suppression
12. p21 is a universal inhibitor of cyclin kinases
13. 1cyclin-dependent kinases
14. p53 in signaling checkpoint arrest or apoptosis
15. Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence
16. p21Waf1/Cip1/sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53
17. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53
18. Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs
19. 1arrest and long-term induction of Cip1 in normal human fibroblasts
20. Oxidative DNA damage and senescence of human diploid fibroblast cells
21. Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts
22. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
23. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts
24. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence
25. A cell cycle regulator potentially involved in genesis of many tumor types
26. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
27. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
28. Genetic heterogeneity in familial malignant melanoma
29. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds
30. Schedule dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines
31. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors
32. p53 status and the efficacy of cancer therapy in vivo
33. DNA topoisomerase inhibitors induce reversible senescence in normal human fibroblasts
34. 2arrest after DNA damage
35. RNA synthesis block by 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells
36. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
37. Inhibition of cyclin-dependent kinases by p21
38. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product
39. The retinoblastoma protein and cell cycle control
40. 1/S cell cycle mediators in cellular senescence
41. Regulation of c-fos expression in senescing Werner syndrome fibroblasts differs from that observed in senescing fibroblasts from normal donors
42. 2cell cycle arrest in p53-deficient cells
43. 2/M-phase transition
44. 2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication
45. A phase II study of interferon-a, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: Clinical data and laboratory evidence of protease activation
46. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study